See more : Tamboran Resources Limited (TBN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Vor Biopharma Inc. (VOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vor Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mewah International Inc. (MV4.SI) Income Statement Analysis – Financial Results
- AB Sagax (publ) (0QDX.IL) Income Statement Analysis – Financial Results
- Warrior Technologies Acquisition Company (WARR) Income Statement Analysis – Financial Results
- Penpower Technology LTD. (5211.TWO) Income Statement Analysis – Financial Results
- Sunset Island Group, Inc. (SIGO) Income Statement Analysis – Financial Results
Vor Biopharma Inc. (VOR)
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| Gross Profit | -3.49M | -8.96M | -4.45M | -1.39M | -91.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 94.32M | 64.55M | 47.53M | 31.62M | 6.20M | 2.43M |
| General & Administrative | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Cost & Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Interest Income | 8.17M | 1.32M | 119.00K | 29.00K | 154.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 1.00M |
| Depreciation & Amortization | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| EBITDA | -114.37M | -90.89M | -67.58M | -41.95M | -10.17M | -2.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.04M | -93.42M | -69.02M | -43.37M | -10.42M | -2.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.17M | 1.32M | 119.00K | 29.00K | -422.00K | -1.29M |
| Income Before Tax | -117.86M | -92.09M | -68.90M | -43.34M | -10.84M | -4.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -119.00K | 427.70K | 608.00K | -289.00K |
| Net Income | -117.86M | -90.77M | -68.78M | -43.34M | -11.45M | -4.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| EPS Diluted | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| Weighted Avg Shares Out | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
| Weighted Avg Shares Out (Dil) | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink...
Vor to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:
Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 186.2% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC)...
Vor to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor's President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor's Chief Financial Officer, will...
Vor to Present New Platform and Preclinical Data at ASH
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the upcoming presentation of new data from its novel engineered hematopoietic stem cell (eHSC) platform at the American Society...
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's Senior Vice President of Program and Alliance Management. Dr. Schmelmer has...
Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US
The FDA has granted Fast Track designation to Vor Biopharma's (NASDAQ: VOR) VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML). VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33.
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2021, and provided a business update.
Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia
Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies...
Source: https://incomestatements.info
Category: Stock Reports